GET DAILY SIGNALSGILD vs AMGN Stock Comparison: Earnings Preview Ahead of Q4
Key Takeaways
-
Gilead Sciences (GILD): Q4 2025 earnings due February 10, consensus EPS $1.83, revenue $7.68B. Growth driven by HIV franchise; oncology investments like Trodelvy may offer upside.
-
Amgen (AMGN): Reported Q4 2025 EPS $5.29 vs $4.73 expected, revenue $9.9B (+9% YoY). Strong 2026 guidance: $37–38.4B revenue, $21.60–23.00 non-GAAP EPS.
-
Valuation: GILD trades at lower P/E (~18–19), AMGN higher (~24). Both offer dividends and Overweight analyst ratings.
-
Market focus: Pipeline progress, biosimilar pressures, and franchise resilience in a high-interest-rate environment.
Why This Comparison Matters
GILD and AMGN, two biotech leaders, offer contrasting profiles. GILD relies heavily on its HIV portfolio and emerging oncology, providing stable, defensive growth. AMGN’s diversified blockbuster portfolio spans immunology, oncology, and cardiovascular, delivering volume-driven earnings momentum. Comparing the two highlights strategic differences in growth, pipeline execution, and exposure to biosimilars, helping investors assess defensive biotech positioning.
GILD Earnings Focus
Gilead reports Q4 and full-year 2025 results after market close on February 10, followed by a 4:30 p.m. ET call. Key metrics include:
-
Biktarvy sales in HIV
-
Trodelvy oncology performance
-
Full-year guidance updates
Historical performance shows three EPS beats in the last four quarters (e.g., Q3 surprise $2.47 vs $2.15), though post-earnings stock moves are typically modest (~±4.4%). Investors will watch pipeline momentum to offset declining Veklury revenue.
AMGN Context
Amgen reported strong Q4 results on February 3, 2026:
-
EPS: $5.29 non-GAAP vs $4.73 expected
-
Revenue: $9.9B, +9% YoY
-
Volume: 10% growth across 18 top-performing products, 14 blockbusters >$1B each
2026 guidance underscores robust portfolio strength: $37–38.4B revenue and $21.60–23.00 EPS. Obesity therapy MariTide and recent approvals further bolster growth, despite minor post-earnings profit-taking.
GILD offers value and steady dividends, while AMGN benefits from diversified growth and recent earnings momentum. Risks include biosimilars for AMGN’s Prolia/Xgeva and competitive pressures in HIV for GILD.
AI Trading Bot Insight
Tickeron’s Trend Trader for Beginners Strategy for Large Cap Stocks (60-min TA) targets large-cap biotech like AMGN, using trend-following and machine learning to optimize entry/exit points. Backtested returns show +27% annualized, offering a beginner-friendly automated approach to capturing medium-term momentum.
Verdict
AI models currently favor AMGN for superior earnings quality, pipeline diversity, and strong 2026 guidance, providing stability in a volatile biotech market. GILD remains attractive for value-oriented investors ahead of earnings, but AMGN’s broad portfolio and recent momentum tilt near-term probabilities in its favor.
Disclaimers and Limitations
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 57 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 35 of 54 cases over the following month. The odds of a continued upward trend are 65%.
Following a +7.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 129 of 264 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.856) is normal, around the industry mean (-1.376). GILD's P/E Ratio (-65.261) is considerably lower than the industry average of (21.842). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.039) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement